News

UCB’s GEMZ Phase 3 Trial Shows Promising Results for Fenfluramine in Treating CDKL5 Deficiency Disorder

UCB Announces Promising Phase 3 Results for Fenfluramine in CDKL5 Deficiency Disorder, Marking a Major Step Forward in Rare Epilepsy Treatment UCB, a global biopharmaceutical company committed to developing innovative therapies for neurological and immunological conditions, has announced positive top-line…

Read MoreUCB’s GEMZ Phase 3 Trial Shows Promising Results for Fenfluramine in Treating CDKL5 Deficiency Disorder

Biogen Shares Promising Nusinersen Data in Continued Mission to Improve Lives of Those with

Biogen Unveils New Data Underscoring the Long-Term Benefits and Advancements of Nusinersen in Spinal Muscular Atrophy Treatment Biogen, a global leader in neuroscience, has announced compelling new data that reinforces the clinical value and therapeutic potential of nusinersen, a pioneering…

Read MoreBiogen Shares Promising Nusinersen Data in Continued Mission to Improve Lives of Those with

Viatris Announces Success in Second Pivotal Phase 3 Trial of MR-141 Targeting Presbyopia

Viatris Reports Positive Top-Line Results from Pivotal Phase 3 VEGA-3 Trial of MR-141 for Presbyopia, Underscoring Its Potential as a Non-Invasive Vision Correction Therapy Viatris, a global healthcare company committed to increasing access to high-quality medicines and health solutions worldwide,…

Read MoreViatris Announces Success in Second Pivotal Phase 3 Trial of MR-141 Targeting Presbyopia

BeOne Medicines Presents Transformative Oncology Portfolio at Research & Development Day

BeOne Medicines Showcases Bold Vision and Expansive Oncology Pipeline at 2025 R&D Day BeOne Medicines Ltd., a global oncology-focused biopharmaceutical company, delivered a comprehensive update to investors today during its highly anticipated Research and Development (R&D) Day. The event spotlighted…

Read MoreBeOne Medicines Presents Transformative Oncology Portfolio at Research & Development Day

Merck’s ENFLONSIA Receives ACIP Recommendation for Protecting Infants from Severe RSV

Merck’s ENFLONSIA Receives ACIP Endorsement for RSV Prevention in Infants, Marking a Major Milestone in Pediatric Infectious Disease Prevention U.S. CDC panel backs long-acting monoclonal antibody to protect infants during their first RSV season; drug also included in federal Vaccines…

Read MoreMerck’s ENFLONSIA Receives ACIP Recommendation for Protecting Infants from Severe RSV

Biogen Advances Investigational SMA Therapy to Registrational Trials After Positive Phase 1 Data

Biogen Reports Promising Interim Phase 1 Results for Salanersen in Spinal Muscular Atrophy, Prepares for Registrational Trials Biogen has announced encouraging topline results from its Phase 1 clinical trial evaluating salanersen (BIIB115/ION306), an investigational antisense oligonucleotide (ASO) therapy for spinal…

Read MoreBiogen Advances Investigational SMA Therapy to Registrational Trials After Positive Phase 1 Data